AR and prostate carcinoma: Previous studies showed that combination treatment with an AR inhibitor (enzalutamide), antibiotic (clofoctol) or a natural product (Nobiletin) promoted the anti-cancer effects of sorafenib in castration-resistant prostate cancer (47–49).